摘要
目的观察瑞舒伐他汀和阿托伐他汀对急性冠状动脉综合征患者血脂、炎症因子和冠状动脉支架植入术后再狭窄的影响。方法 111例急性冠状动脉综合征支架植入患者,随机分为瑞舒伐他汀组(瑞舒伐他汀20 mg+常规用药)和阿托伐他汀组(阿托伐他汀40 mg+常规用药),术前和术后6个月分别检查总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和超敏C反应蛋白(hs-CRP),复查冠状动脉造影,测量支架内再狭窄率,记录心绞痛发生率,比较两组之间的差别。结果瑞舒伐他汀组TC、TG、LDL-C、Hs-CRP和心绞痛发生率均较阿托伐他汀组低(P<0.05),HDL-C高于阿托伐他汀组,支架内再狭窄率两组差异无统计学意义(P>0.05)。结论瑞舒伐他汀较阿托伐他汀有更强的调脂和抗炎作用,能减少心绞痛的发生率。
Objective To observe the effect of Rosuvastatin and Atorvastatin on blood lipid, CRP and restenosis after coro- nary stenting of patients with acute coronary syndrome. Methods One hundred and eleven patients with acute coronary syndrome after PCI were randomly divided into Rosuvastatin group （Rosuvastatin 20 rag＋routine treatment） and Atorvastatin group （Atorvastatin 40 rag＋routine treatment）. Before and after operation for 6 months, TC, TG, LDL-C, HDL-C and hs- CRP were detected, the coronarography was rechecked, the rate of restenosis was measured, the incidence of angina was recorded, and the differences of the two groups were compared. Results TC, TG, LDL-C, hs-CRP and the incidence of angina in Rosuvastatin group were all lower than those in Atorvastatin group （P 〈 0.05）, while HDL-C was higher than that in Atorvastatin group. But there was no statistically significant difference of the incidence of restenosis between the two groups （P 〉 0.05）. Conclusion Rosuvastatin has stronger effects in regulating lipid, anti-inflammation and lowering incidence of angina than Atorvastatin.
出处
《中国当代医药》
2012年第19期30-31,33,共3页
China Modern Medicine
